natgillin/translations-raw huggingface dataset:
At 48 weeks, the difference for dapagliflozin as add-on to metformin plus sitagliptin compared with placebo was -2.07 kg. At 102 weeks, the difference for dapagliflozin as add-on to metformin compared with placebo or as add-on to insulin compared with placebo was -2.14 and -2.88 kg, respectively. 
Po 102 tednih je bila razlika z dapagliflozinom kot dodatkom metforminu v primerjavi s placebom -2,14 kg in kot dodatkom insulinu v primerjavi s placebom -2,88 kg.
Excipient(s) with known effect: Xigduo contains less than 1 mmol sodium (23 mg) per dose, i.e. is essentially ‘sodium-free'. 
Zdravilo Xigduo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni ‘brez natrija'.
Tell your doctor before you start taking this medicine if you have any of these signs. 
Če imate katerega od teh znakov, morate to povedati zdravniku, preden začnete jemati to zdravilo.
You may need more frequent blood glucose and kidney function tests, or your doctor may adjust the dosage of Xigduo. 
Morda boste morali pogosteje opravljati preiskave glukoze v krvi in delovanja ledvic,
Cardiovascular and renal outcomes 
Srčno-žilni in ledvični izidi
Effect of other medicinal products on dapagliflozin Interaction studies conducted in healthy subjects, using mainly a single-dose design, suggest that the pharmacokinetics of dapagliflozin are not altered by pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin. 
Študije medsebojnega delovanja pri zdravih preiskovancih, opravljene v glavnem po raziskovalnem načrtu z enim odmerkom, kažejo, da pioglitazon, sitagliptin, glimepirid, voglibos, hidroklorotiazid, bumetanid, valsartan ali simvastatin ne spremenijo farmakokinetike dapagliflozina.
For the add-on to metformin study, HbA1c reductions were sustained through Week 102 (-0.78% and 0.02% adjusted mean change from baseline for dapagliflozin 10 mg and placebo, respectively). 
V študiji dodatka metforminu se je znižanje HbA1c ohranilo do 102. tedna (korigirana povprečna sprememba od izhodišča z 10 mg dapagliflozina -0,78 % in s placebom 0,02 %).
QD=once daily, QW=once weekly, N=number of patients, CI=confidence interval. 
N = število bolnikov, IZ = interval zaupanja.
Combination therapy of dapagliflozin 10 mg and prolonged-release exenatide resulted in significantly greater reductions in FPG at Week 28: -3.66 mmol/L (-65.8 mg/dL), compared to -2.73 mmol/L (-49.2 mg/dL) for dapagliflozin alone (p < 0.001) and -2.54 mmol/L (-45.8 mg/dL) for exenatide alone (p < 0.001). 
Pri kombiniranem zdravljenju z 10 mg dapagliflozina in eksenatidom v obliki s podaljšanim sproščanjem je bilo v 28. tednu doseženo značilno večje znižanje glukoze v plazmi na tešče: -3,66 mmol/l (-65,8 mg/dl) v primerjavi z -2,73 mmol/l (-49,2 mg/dl) za dapagliflozin sam (p < 0,001) in -2,54 mmol/l (-45,8 mg/dl) za eksenatid sam (p < 0,001).
The following adverse reactions have been identified in the placebo-controlled dapagliflozin plus metformin clinical studies, dapagliflozin clinical studies and metformin clinical studies and post-marketing experience. 
V s placebom kontroliranih kliničnih študijah kombinacije dapagliflozina in metformina, kliničnih študijah dapagliflozina, kliničnih študijah metformina in med obdobjem po odobritvi dovoljenja za promet so ugotovili naslednje neželene učinke.
Diabetic ketoacidosis b,k,l 
pomanjkanje volumna b,e žeja diabetična ketoacidoza b,k,l laktacidoza pomanjkanje vitamina B12
Dapagliflozin as an add-on to metformin alone or metformin plus sitagliptin, sulphonylurea or insulin (with or without additional oral glucose-lowering medicinal products, including metformin) resulted in statistically significant body weight reduction up to 24 weeks (p < 0.0001, Tables 4, 5 and 6). 
Dapagliflozin kot dodatek metforminu samemu ali metforminu v kombinaciji s sitagliptinom, sulfonilsečnino ali insulinom (z dodatnimi peroralnimi zdravili za znižanje glukoze (vključno z metforminom) ali brez njih) je do 24. tedna statistično značilno znižal telesno maso (p < 0,0001, preglednice 4, 5 in 6).
Rates of adverse events including dehydration or hypotension were similar to placebo, and there were no clinically meaningful dose-related changes in laboratory parameters, including serum electrolytes and biomarkers of renal function. 
Ugotovili niso nobenih klinično pomembnih z odmerkom povezanih sprememb laboratorijskih parametrov, vključno z elektroliti v serumu in biološkimi označevalci delovanja ledvic.
The mean plasma terminal half-life (t1/2) for dapagliflozin was 12.9 hours following a single oral dose of dapagliflozin 10 mg to healthy subjects. 
Po enkratnem peroralnem odmerku 10 mg dapagliflozina pri zdravih osebah je bil povprečni plazemski terminalni razpolovni čas (t1/2) dapagliflozina 12,9 ure.
Results at Week 24 of a placebo-controlled study of dapagliflozin in diabetic patients with an eGFR ≥ 45 to < 60 mL/min/1.73 m 
Rezultati s placebom kontrolirane študije dapagliflozina pri sladkornih bolnikih z eGFR od ≥ 45 do < 60 ml/min/1,73 m2 po 24 tednih
All treatment groups had a reduction in HbA1c compared to baseline. 
V primerjavi z izhodiščem se je HbA1c znižal v vseh zdravljenih skupinah.
a) in a placebo-controlled study of dapagliflozin in combination with insulin (alone or with oral glucose-lowering medicinal products, including metformin) 
Rezultati s placebom kontrolirane študije dapagliflozina v kombinaciji z insulinom (samim ali skupaj s peroralnim antidiabetikom, vključno z metforminom) po 24 tednih (LOCF
Maximum daily dose is 2000 mg. 
Največji dnevni odmerek je 2000 mg.
Dapagliflozin 10 mg + insulin ± oral glucose-lowering medicinal products 
Dapagliflozin 10 mg + insulin ± peroralni antidiabetiki
Talk to your doctor, pharmacist or nurse before taking Xigduo, and during treatment: 
Pred začetkom jemanja zdravila Xigduo in med zdravljenjem se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro:
Xigduo 5 mg/850 mg film-coated tablets and Xigduo 5 mg/1,000 mg film-coated tablets are available in PVC/PCTFE/Alu blister. 
Filmsko obložene tablete Xigduo 5 mg/850 mg in Xigduo 5 mg/1000 mg so na voljo v pretisnih omotih iz PVC/PCTFE/Alu.
Rare cases of diabetic ketoacidosis (DKA), including life-threatening and fatal cases, have been reported in patients treated with sodium-glucose co-transporter 2 (SGLT2) inhibitors, including dapagliflozin. 
Pri bolnikih, zdravljenih z zaviralci natrij-glukoznega soprenašalca 2 (SGLT2 - sodium glucose co-transporter 2) (vključno z dapagliflozinom), so poročali o redkih primerih diabetične ketoacidoze (DKA), med njimi tudi o smrtno nevarnih in smrtnih primerih.
Additionally, at Week 24, clinically relevant and statistically significant improvements in mean changes from baseline in body weight were seen with dapagliflozin and metformin combination treatments compared with control. 
Poleg tega so 24. teden s kombinacijo dapagliflozina in metformina v primerjavi s kontrolami ugotovili klinično pomembno in statistično značilno povprečno spremembo telesne mase od izhodišča.
• redness of the skin (erythema), itching or an itchy rash (hives) 
• pordelost kože (rdečica), srbenje ali srbeč izpuščaj (koprivnica)
Dapagliflozin as an add-on with either metformin alone, metformin in combination with sitagliptin, sulphonylurea or insulin (with or without additional oral glucose-lowering medicinal products, including metformin) resulted in statistically significant mean reductions in HbA1c at 24 weeks compared with subjects receiving placebo (p < 0.0001; Tables 4, 5 and 6). 
Dapagliflozin kot dodatek bodisi metforminu samemu, metforminu v kombinaciji s sitagliptinom, sulfonilsečnino ali insulinom (z dodatnimi peroralnimi antidiabetiki (vključno z metforminom) ali brez njih) je po 24 tednih statistično značilno znižal HbA1c v primerjavi s prejemniki placeba (p < 0,0001, preglednice 4, 5 in 6).
At Week 208, adjusted mean change from baseline in HbA1c was -0.10% for dapagliflozin and 0.20% for glipizide, respectively. 
208. teden je bila korigirana povprečna sprememba HbA1c od izhodišča z dapagliflozinom -0,10 % in z glipizidom 0,20 %.
Xigduo 5 mg/850 mg film-coated tablets 
Xigduo 5 mg/850 mg filmsko obložene tablete
Combination therapy of dapagliflozin 10 mg and prolonged-release exenatide resulted in a significantly greater reduction in systolic blood pressure at Week 28 (-4.3 mmHg) compared to dapagliflozin alone (-1.8 mmHg, p < 0.05) and prolonged-release exenatide alone (-1.2 mmHg, p < 0.01). 
Pri kombiniranem zdravljenju z 10 mg dapagliflozina in eksenatidom v obliki s podaljšanim sproščanjem je bilo v 28. tednu doseženo značilno večje znižanje sistoličnega krvnega tlaka (-4,3 mmHg) v primerjavi z dapagliflozinom samim (-1,8 mmHg, p < 0,05) ali eksenatidom v obliki s podaljšanim sproščanjem samim (-1,2 mmHg, p < 0,01).
Xigduo should not be initiated in patients with GFR < 60 mL/min and should be discontinued at GFR persistently below 45 mL/min (see section 4.2). 
Zdravljenje je treba prekiniti pri GFR trajno pod 45 ml/min (glejte poglavje 4.2).
Despite the presence of hyperglycaemia in type 2 diabetes, reabsorption of filtered glucose continues. 
Reabsorpcija filtrirane glukoze se pri sladkorni bolezni tipa 2 nadaljuje kljub hiperglikemiji.
Hydroxypropyl cellulose (E463) Microcrystalline cellulose (E460(i)) 
Jedro tablete hidroksipropilceluloza (E463) mikrokristalna celuloza (E460(i)) magnezijev stearat (E470b) natrijev karboksimetilškrob, vrsta A
Dapagliflozin did not show any toxicity in healthy subjects at single oral doses up to 500 mg (50 times the maximum recommended human dose). 
Enkratni peroralni odmerki dapagliflozina do 500 mg (to je 50-kratni največji priporočeni odmerek za človeka) pri zdravih osebah niso povzročili toksičnih učinkov.
Maximum daily dose is 3000 mg. 
Največji dnevni odmerek je 3000 mg.
HbA1c (%) Baseline (mean) Change from baseline Difference from placebo d 
HbA1c (%) Izhodišče (povprečje) Sprememba od izhodišča Razlika v primerjavi s placebom d
The glycaemic efficacy of dapagliflozin is dependent on renal function, and efficacy is reduced in patients who have moderate renal impairment and is likely absent in patients with severe renal impairment. 
Pri bolnikih z zmerno okvaro ledvic je njegova učinkovitost manjša, pri bolnikih s hudo okvaro ledvic pa verjetno ni učinkovit.
Baseline (mean) Change from baseline Difference from dapagliflozin c 
Izhodišče (povprečje) Sprememba od izhodišča Razlika od dapagliflozina c
Xigduo 5 mg/1,000 mg film-coated tablets 
Xigduo 5 mg/1000 mg filmsko obložene tablete
• if you have very high levels of glucose in your blood which may make you dehydrated (lose too much body fluid). 
Zaradi tega lahko dehidrirate (izgubite preveč tekočine).
Maximum daily dose is 1000 mg. 
Največji dnevni odmerek je 1000 mg.
In a dedicated study in diabetic patients with an eGFR ≥ 45 to < 60 mL/min/1.73 m2, treatment with dapagliflozin demonstrated reductions in FPG at Week 24: -1.19 mmol/L (-21.46 mg/dL) compared to -0.27 mmol/L (-4.87 mg/dL) for placebo (p=0.001). 
V namenski študiji pri sladkornih bolnikih z eGFR od ≥ 45 do < 60 ml/min/1,73 m2 je zdravljenje z dapagliflozinom 24. teden doseglo znižanje glukoze v plazmi na tešče: sprememba je znašala -1,19 mmol/l (-21,46 mg/dl) v primerjavi z -0,27 mmol/l (-4,87 mg/dl) s placebom (p = 0,001).
Hypoglycaemia (when used with SU or insulin) 
Presnovne in prehranske motnje hipoglikemij a (med uporabo s sulfonilsečni nami ali insulinom)
These are the signs of low blood sugar: - shaking, sweating, feeling very anxious, fast heart beat - feeling hungry, headache, change in vision - a change in your mood or feeling confused. 
Znaki nizkega krvnega sladkorja so: - tresenje, znojenje, občutek hude tesnobe, hitro bitje srca - lakota, glavobol, spremembe vida - sprememba razpoloženja ali zmedenost Zdravnik vam bo povedal, kako zdraviti nizek krvni sladkor in kaj storiti, če se vam pojavi kateri od zgoraj opisanih znakov.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja in razvoj ne kažejo posebnega tveganja za človeka.
In a dedicated study in diabetic patients with an eGFR ≥ 45 to < 60 mL/min/1.73 m2, treatment with dapagliflozin demonstrated reductions in seated systolic blood pressure at Week 24: -4.8 mmHg compared to -1.7 mmHg for placebo (p < 0.05). 
V namenski študiji pri sladkornih bolnikih z eGFR od ≥ 45 do < 60 ml/min/1,73 m2 je zdravljenje z dapagliflozinom 24. teden doseglo znižanje sistoličnega krvnega tlaka sede: sprememba je znašala -4,8 mmHg v primerjavi z -1,7 mmHg s placebom (p < 0,05).
In an add-on to insulin study up to 104 weeks, episodes of major hypoglycaemia were reported in 0.5% and 1.0% of subjects in dapagliflozin 10 mg plus insulin at Weeks 24 and 104, respectively, and in 0.5% of subjects treated with placebo plus insulin groups at Weeks 24 and 104. 
V študiji dodatka k insulinu do 104 tedne so hude hipoglikemije do 24. oziroma 104. tedna zabeležili pri 0,5 % oziroma 1,0 % prejemnikov kombinacije 10 mg dapagliflozina in insulina ter pri 0,5 % prejemnikov kombinacije placeba in insulina.
Reported in the cardiovascular outcomes study in patients with type 2 diabetes. 
Glejte poglavje 4.4 O tem so poročali v študiji srčno-žilnih izidov pri bolnikih s sladkorno boleznijo tipa 2.
At Week 104, adjusted mean change from baseline in HbA1c was -0.32% for dapagliflozin and -0.14% for glipizide, respectively. 
104. teden je bila korigirana povprečna sprememba HbA1c od izhodišča z dapagliflozinom -0,32 % in z glipizidom -0,14 %.
At steady-state (20 mg once-daily dapagliflozin for 7 days), subjects with type 2 diabetes mellitus and mild, moderate or severe renal impairment (as determined by iohexol plasma clearance) had mean systemic exposures of dapagliflozin of 32%, 60% and 87% higher, respectively, than those of subjects with type 2 diabetes mellitus and normal renal function. 
V primerjavi z bolniki s sladkorno boleznijo tipa 2 z normalnim delovanjem ledvic so imeli v stanju dinamičnega ravnovesja (uporaba dapagliflozina 20 mg enkrat na dan 7 dni) bolniki s sladkorno boleznijo tipa 2 z blago okvaro ledvic sistemsko izpostavljenost dapagliflozinu večjo za 32 %, tisti z zmerno okvaro za 60 % in tisti s hudo okvaro za 87 % (stopnja okvare je bila ugotovljena s plazemskim očistkom ioheksola).
Therefore, close monitoring of glycaemic control, dose adjustment within the recommended posology and changes in diabetic treatment should be considered when cationic medicinal products that are eliminated by renal tubular secretion are coadministered. 
Zato je treba v primeru sočasne uporabe kationskih zdravil, ki se izločajo z ledvično tubularno sekrecijo, natančno kontrolirati urejenost glikemije, odmerek prilagoditi v okviru priporočenega odmerjanja in razmisliti o spremembah zdravljenja sladkorne bolezni.
Factors that may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation of metformin in patients with GFR < 60 mL/min. 
Pri bolnikih z GFR < 60 ml/min je treba pred uvedbo zdravila Xigduo pregledati dejavnike, ki lahko povečajo tveganje za laktacidozo (glejte poglavje 4.4).
In the 13-study safety pool, reactions suggestive of volume depletion (including, reports of dehydration, hypovolaemia or hypotension) were reported in 1.1% and 0.7% of subjects who received dapagliflozin 10 mg and placebo, respectively; serious reactions occurred in < 0.2% of subjects balanced between dapagliflozin 10 mg and placebo (see section 4.4). 
V kumulativni obravnavi 13 študij o varnosti so o učinkih, ki so nakazovali pomanjkanje volumna (vključno z dehidracijo, hipovolemijo ali hipotenzijo) poročali pri 1,1 % oseb, ki so prejemale 10 mg dapagliflozina, in 0,7 % oseb, ki so prejemale placebo.
Combination therapy with prolonged-release exenatide In a 28-week, double-blind, active comparator-controlled study, the combination of dapagliflozin and prolonged-release exenatide (a GLP-1 receptor agonist) was compared to dapagliflozin alone and prolonged-release exenatide alone in subjects with inadequate glycaemic control on metformin alone (HbA1c ≥ 8% and ≤ 12%). 
Kombinirano zdravljenje z eksenatidom v obliki s podaljšanim sproščanjem Pri preiskovancih, ki glikemije niso imeli urejene s samim metforminom (HbA1c ≥ 8 % in ≤ 12 %), so v 28-tedenski, dvojno slepi, z učinkovino kontrolirani študiji primerjali kombinacijo dapagliflozina in eksenatida (agonist receptorjev GLP-1) v obliki s podaljšanim sproščanjem s samim dapagliflozinom in samim eksenatidom v obliki s podaljšanim sproščanjem.
Xigduo 5 mg/1,000 mg film-coated tablets Polyvinyl alcohol (E1203) Macrogol 3350 (E1521) Talc (E553b) 
Xigduo 5 mg/1000 mg filmsko obložene tablete polivinilalkohol (E1203) makrogol 3350 (E1521) smukec (E553b) titanov dioksid (E171) rumeni železov oksid (E172)
• increases in urea (shown in laboratory blood tests) 
• zvišanje sečnine (to se pokaže v laboratorijskih preiskavah)
Approximately 70 g of glucose was excreted in the urine per day (corresponding to 280 kcal/day) at a dapagliflozin dose of 10 mg/day in subjects with type 2 diabetes mellitus for 12 weeks. 
Med 12-tedensko uporabo 10 mg dapagliflozina na dan se je pri bolnikih s sladkorno boleznijo tipa 2 z urinom izločilo približno 70 g glukoze na dan (to ustreza 280 kcal/dan).
Each Xigduo 5 mg/850 mg film-coated tablet (tablet) contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin and 850 mg metformin hydrochloride. 
Ena filmsko obložena tableta (tableta) zdravila Xigduo 5 mg/850 mg vsebuje dapagliflozin-propandiol monohidrat v količini, ki ustreza 5 mg dapagliflozina, in 850 mg metforminijevega klorida.
Xigduo 5 mg/850 mg film-coated tablets Xigduo 5 mg/1,000 mg film-coated tablets 
Xigduo 5 mg/850 mg filmsko obložene tablete Xigduo 5 mg/1000 mg filmsko obložene tablete
Dapagliflozin exposure increased proportional to the increment in dapagliflozin dose over the range of 0.1 to 500 mg and its pharmacokinetics did not change with time upon repeated daily dosing for up to 24 weeks. 
Izpostavljenost dapagliflozinu se je v razponu odmerkov od 0,1 do 500 mg povečevala sorazmerno povečanju odmerka.
At Weeks 48 and 104, the insulin dose remained stable compared to baseline in subjects treated with dapagliflozin 10 mg at an average dose of 76 IU/day. 
Pri preiskovancih, zdravljenih z 10 mg dapagliflozina, je ostal odmerek insulina 48. in 104. teden v primerjavi z izhodiščem stabilen; povprečni odmerek je bil 76 i.e./dan.
Body weight (kg) Baseline (mean) Change from baseline Difference from placebo c 
Telesna masa (kg) Izhodišče (povprečje) Sprememba od izhodišča Razlika v primerjavi s placebom
Necrotising fasciitis of the perineum (Fournier's gangrene) 
*,b,d glivična okužba nekrotizirajoči fasciitis presredka (Fournierjeva gangrena)
Concomitant use not recommended 
Nepriporočljive kombinacije
Each Xigduo 5 mg/1,000 mg film-coated tablet (tablet) contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin and 1,000 mg metformin hydrochloride. 
Ena filmsko obložena tableta (tableta) zdravila Xigduo 5 mg/1000 mg vsebuje dapagliflozin-propandiol monohidrat v količini, ki ustreza 5 mg dapagliflozina, in 1000 mg metforminijevega klorida.
Additional developmental toxicity was limited to dose-related reductions in pup body weights, and observed only at doses ≥ 15 mg/kg/day (associated with pup exposures that are ≥ 29 times the human values at the maximum recommended human dose). 
≥ 15 mg/kg/dan (to je povezano z izpostavljenostjo mladičev, ki je ≥ 29-krat večja od izpostavljenosti človeka pri največjem priporočenem odmerku za človeka).
These are signs of a severe infection of the urinary tract: - fever and/or chills - burning sensation when passing water (urinating) - pain in your back or side. 
Znaki hude okužbe sečil so: - zvišana telesna temperatura in/ali mrzlica - pekoč občutek pri odvajanju vode (uriniranju) - bolečine v hrbtu ali ledveno Kri v urinu se sicer ne pojavi pogosto, a če jo opazite, morate o tem takoj obvestiti zdravnika.
Dapagliflozin is not recommended. 
Uporaba dapagliflozina ni priporočljiva.
•Xigduo5mg/850mg are 9.5x20mm oval, brown film-coated tablets. 
• Zdravilo Xigduo 5 mg/850 mg so 9,5 x 20 mm velike, ovalne, rjave filmsko obložene tablete.
Results of (LOCF a) placebo-controlled studies up to 24 weeks of dapagliflozin in add-on combination with metformin or metformin plus sitagliptin Add-on combination 
Rezultati s placebom kontrolirane študije dapagliflozina kot dodatek metforminu samemu ali metforminu v kombinaciji s sitagliptinom po 24 tednih (LOCF
Dysuria Polyuria 
Bolezni sečil dizurija poliurija
Fifty percent of subjects were on insulin monotherapy at baseline; 50% were on 1 or 2 oral glucose-lowering medicinal product(s) in addition to insulin: Of this latter group, 80% were on metformin alone, 12% were on metformin plus sulphonylurea therapy, and the rest were on other oral glucose-lowering medicinal products. 
Petdeset odstotkov bolnikov je bilo izhodiščno na monoterapiji z insulinom; 50 % jih je poleg insulina jemalo 1 ali 2 peroralna antidiabetika.
Each tablet contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin and 850 mg of metformin hydrochloride. 
Ena tableta vsebuje dapagliflozin-propandiol monohidrat v količini, ki ustreza 5 mg dapagliflozina, in 850 mg metforminijevega klorida.
Xigduo 5 mg/850 mg film-coated tablets Xigduo 5 mg/1,000 mg film-coated tablets dapagliflozin/metformin hydrochloride 
Xigduo 5 mg/850 mg filmsko obložene tablete Xigduo 5 mg/1000 mg filmsko obložene tablete dapagliflozin/metforminijev klorid
The combination of dapagliflozin 10 mg and prolonged-release exenatide demonstrated significantly greater weight reductions compared to either agent alone (Table 8). 
Pri kombiniranem zdravljenju z 10 mg dapagliflozina in eksenatidom v obliki s podaljšanim sproščanjem je bilo doseženo značilno večje zmanjšanje telesne mase kot pri kateri od obeh učinkovin samih (preglednica 8).
In patients with normal renal function or mild renal impairment (baseline eGFR ≥ 60 mL/min/1.73 m2) this grouping of reactions were reported in 1.3% and 0.8% of patients who received dapagliflozin 10 mg and placebo, respectively. 
Pri bolnikih z normalnim delovanjem ledvic ali blago okvaro ledvic (izhodiščna ocenjena hitrost glomerularne filtracije [eGFR] ≥ 60 ml/min/1,73 m2) je bila ta skupina učinkov opisana pri 1,3 % bolnikov, ki so prejemali 10 mg dapagliflozina, in pri 0,8 % tistih, ki so prejemali placebo.Te reakcije so bile pogostejše pri bolnikih z izhodiščno ocenjeno hitrostjo glomerularne filtracije [eGFR] ≥ 30 in < 60 ml/min/1,73 m2 (18,5 % z 10 mg dapagliflozina in 9,3 % s placebom).
Dapagliflozin plus metformin 
Dapagliflozin skupaj z metforminom
Change from baseline Difference from glipizide + metformin c 
Razlika v primerjavi s kombinacijo glipizid + metformin
Xigduo 5 mg/850 mg film-coated tablets Polyvinyl alcohol (E1203) Macrogol 3350 (E1521) Talc (E553b) 
Xigduo 5 mg/850 mg filmsko obložene tablete polivinilalkohol (E1203) makrogol 3350 (E1521) smukec (E553b) titanov dioksid (E171) rumeni železov oksid (E172) rdeči železov oksid (E172)
Skin and subcutaneous tissue disorders 
Bolezni mišičnoskeletnega sistema in vezivnega tkiva bolečine v hrbtu
Mean difference in change from baseline between combination and single active agent (95% CI) 
Odstotek spremembe od izhodišča Razlika v odstotku spremembe v primerjavi s placebom (95 % IZ)
Very common Common Uncommon 
Zelo pogosti Pogosti
How to store Xigduo 
Shranjevanje zdravila Xigduo
Musculoskeletal and 
• mišične krče
Each tablet contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin and 1,000 mg of metformin hydrochloride. 
Ena tableta vsebuje dapagliflozin-propandiol monohidrat v količini, ki ustreza 5 mg dapagliflozina, in 1000 mg metforminijevega klorida.